(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau

(43) International publication date

25 March 2004 (25.03.2004)

PCT

(10) International publication number

WO 2004/024149 A1

(51) International patent classification[7]: A61K 31/424, C07D 498/22, 498/18

(21) International application number: PCT/EP2003/009329

(22) International filing date: 22 August 2003 (22.08.2003)

(25) Language of filing: German

(26) Language of publication: German

(30) Data relating to the priority:
60/405,594 24 August 2002 (24.08.2002) US

(71) Applicant: ZENTARIS GMBH [DE/DE]; Weismüllerstrasse 45, 60314 Frankfurt/Main (DE).

(72) Inventors: IRSCHIK, Herbert; Masurenweg 15, 38302 Wolfenbüttel (DE). JANSEN, Rolf; Falkenbergstrasse 14, 38124 Braunschweig (DE). SASSE, Florenz; Im Rübenkamp 7, 38124 Braunschweig (DE). BAASNER, Silke; Dittersdorfer Strasse 42, 61137 Schöneck (DE). SCHMIDT, Peter; Dittersdorfer Strasse 42, 61137 Schöneck (DE). GÜNTHER, Eckhard; Wingertstrasse 176, 63477 Maintal (DE).

(74) Attorney: ZENTARIS GMBH; Patente und Marken, Meissner Strasse 35, 01445 Radebeul (DE).

(81) Designated states *(national)*: AT, AU, BR, BY, CA, CN, CO, GE, HR, ID, IL, IN, IS, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PH, PL, RU, SG, UA, UZ, YU, ZA.

(84) Designated states *(regional)*: Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:
- *With the International Search Report.*
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*


For an explanation of the two-letter codes and the other abbreviations, reference is made to the explanations ("Guidance Notes on Codes and Abbreviations") at the beginning of each regular edition of the PCT Gazette.

As printed

(54) Title: MEDICAMENT CONTAINING DISORAZOLES AND DERIVATIVES THEREOF FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMORAL DISEASES

(54) Bezeichnung: ARZNEIMITTEL ENTHALTEND DISORALE UND IHRE DERIVATE UND DEREN ANWENDUNG ZUR BEHANDLUNG GUTARTIGER UND BOSÄRTIGER TUMORERKRANKUNGEN

WO 2004/024149 A1



(I)

(57) Abstract: The invention relates to disorazoles of general formula (1) which are used as medicaments, preferably in the treatment of tumoral diseases, especially in the case of medicamentous resistance against other active ingredients and in metastasing carcinoma. Possible uses thereof are not restricted to tumoral diseases.

(57) Zusammenfassung: Gegenstand der Erfindung sind Disorazole der allgemeinen Formel I, die als Arzneimittel bevorzugt zur Behandlung von Tumorerkrankungen, insbesondere bei Arzneimittelresistenz gegen andere Wirkstoffe und bei metastasierendem Karzinom eingesetzt werden. Die möglichen Anwendungen sind nicht auf Tumorerkrankungen beschränkt. (I)

into apoptosis. It has further been possible to show that the antiproliferative action of the disorazoles claimed is based, inter alia, on an effective inhibition of tubulin polymerization. Disorazole E1 is in particular also highly active against paclitaxel- and vindesine-resistant cell lines. It was inventively possible to show that disorazole E1 is highly potent with respect to biological action and thus use as an active compound in a medicament for the control of cancers is possible.

This matters in particular, since disorazole A1 is unsuitable for use as a cytostatic (G. Hoefle, annual report 1999/2000 of the Gesellschaft für Biotechnologische Forschung [Association for Biotechnological Research] GBF, p. 103).

In a therapeutic experiment, using, for example, NCI-H460 tumor xenograft-bearing nude mice – but not restricted thereto - it was possible to observe, however, for disorazole E1 administered i.v, a significant reduction in tumor growth even at doses which produced no weight decrease or perhaps even mortality.

Natural substances are an important source for novel lead structures in pharmaceutical research and are in some cases also directly suitable for the development of a novel medicament (Y.-Z. Shu, J. Nat. Prod., 1998, 61, 1053-1071). It is known that many natural substances possess strongly cytotoxic action (V. J. Ram, S. Kumari, DNP, 2001, 14(8), 465-482).

It is known that natural substances of the group consisting of the disorazoles are isolated from the bacterium of the strain Sorangium cellulosum So ce12 (R. Jansen, H. Irschik, H. Reichenbach, V. Wray, G. Höfle, Liebigs Ann. Chem., 1994, (8), 759-773). In total, 29 disorazoles have been isolated and characterized physicochemically. For the disorazole A1, it was reported that it possesses an antiproliferative action in cell models (H. Irschik, R. Jansen, K. Gerth, G. Höfle, H. Reichenbach, J. Antibiot. 1995, 48(1), 31-35; Y. A. Elnakady, Dissertation, Brunswick Technical University, 2001). Use for the treatment of oncoses was, however, neither disclosed nor suggested. A biological investigation of the other disorazoles was not carried out.

The compounds according to the invention are suitable, without being restricted thereto, for employment as medicaments for the treatment of benign and malignant oncoses or

other antiproliferative disorders in humans and animals. In principle, the compounds according to the invention are suitable for the control of all disorders which are based on the uncontrolled and rapid division of cells and thereby cause pathological conditions. The compounds according to the invention can be employed as an individual substance or in combination with further cytotoxic substances, e.g. cisplatin, carboplatin, doxorubicin, ifosfamide, cyclophosphamide, 5-FU, methotrexate and in particular in combination with inhibitors of signal transduction, such as, for example, Herceptin, Glivec or Iressa, but not restricted thereto.

Synthetic and semisynthetic analogs of the disorazoles also possess antiproliferative action. By means of specific modification of the molecular shape, important properties such as biological inhibitory action, stability and biophysical properties can be modulated. In this manner, therapeutically valuable derivatives of the starting compounds are obtainable. A further aim of the derivatization consists in moderating possible toxic side effects.


The compounds according to the invention can be administered as liquid pharmaceutical forms. This is carried out in the manner suitable in each case in the form of solutions or suspensions.

The compounds according to the invention can be administered in a suitable administration form, preferably into an artery, intraarterally as an injection; into a vein, intravenously as an injection or infusion; into the skin, intracutaneously as an injection; under the skin, subcutaneously as an injection; into the muscle, intramuscularly as an injection; into the abdominal cavity, intraperitoneally as an injection or infusion.

If the compounds of the general formula I according to the invention have at least one asymmetric center, they can be present in the form of their racemates, in the form of the pure enantiomers and/or diastereomers or in the form of mixtures of these enantiomers and/or diastereomers, namely both in substance and as pharmaceutically acceptable salts of these compounds. The mixtures can be present in any desired mixing ratio of the stereoisomers.
If possible, the configurations of each of the double bonds in the compounds according to the invention can independently of one another in each case be E or Z.

If possible, the compounds according to the invention can be present in the form of the tautomers.

According to one embodiment, the invention relates to compounds of the general formula I:



Formula I

in which independently of one another

R1 is:

(i) hydrogen
(ii) OR4
(iii) part of a double bond to C5'

R2, R3 and R4 are:

(i) hydrogen
(ii) unsubstituted or substituted (C_1-C_6)-alkyl,
(iii) (C_1-C_4)-alkyl substituted by one or more fluorine atoms, preferably a trifluoromethyl group,
(iv) unsubstituted or substituted (C_1-C_4)-alkyl-(C_6-C_{14})-aryl, unsubstituted or substituted (C_1-C_4)-alkylheteroaryl,
(v) (C_1-C_4)-alkoxycarbonyl, (C_1-C_4)-alkylaminocarbonyl (C_1-C_4)-alkylamino-thiocarbonyl, (C_1-C_6)-alkylcarbonyl or (C_1-C_6)-alkoxycarbonyl-(C_1-C_6)-alkyl,

it being possible for the substitution of the alkyl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, NH-(C_3-C_{12})-cycloalkyl, OH, O-(C_1-C_{20})-alkyl to take place singly or, on identical or different atoms, multiply by identical or

different substituents, and it being possible for the substitution of an aryl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, OH, O-(C_1-C_{20})-alkyl and/or (C_3-C_8)-heterocyclyl having 1 to 5 heteroatoms, preferably nitrogen, oxygen, sulfur to take place singly or, on identical or different atoms, multiply by identical or different substituents,

and

X, Y are: in each case individually independently of one another or together oxygen, sulfur, two vicinal hydroxyl groups, two vicinal methoxy groups, part of a double bond,


a compound being excluded in which R1 is methoxy, R2, R3 are hydrogen, X is oxygen and Y is the part of a double bond.

The expression "aryl" within the meaning of this invention means aromatic hydrocarbons, inter alia phenyls, naphthyls and anthracenyls. The radicals can also be fused to further saturated, (partially) unsaturated or aromatic ring systems.

The expression "heteroaryl" stands for a 5-, 6- or 7-membered cyclic aromatic radical, which contains at least 1, optionally also 2, 3, 4 or 5 heteroatoms, where the heteroatoms are identical or different. The heterocycle can also be part of a bi- or polycyclic system. Preferred heteroatoms are nitrogen, oxygen and sulfur. It is preferred that the heteroaryl radical is selected from the group which pyrrolyl, furyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, carbazolyl, phenazinyl, phenothiazinyl, acridinyl.


The most preferred compounds according to the general formula I are those which are encountered in the following selection:

(1) Disorazole E1




Formula II: disorazole E1

(2) Disorazole D1




Formula III: disorazole D1

(3) Disorazole A1 is expressly not a subject of this invention.





Formula IV: disorazole A1

The present invention's synthetic and semisynthetic analogs of the disorazoles of the general formula Ia, Ib and Ic are preparable as per scheme 1:





Formula Ia







Formula I





Formula Ib





Formula Ic

Scheme 1

The disorazoles of the general formula I can be converted in a conventional manner to the present invention's derivatives as per the formula Ia, Ib and Ic by replacing the hydrogen on R2, R3 and R4.

For instance, if substituted disorazoles as per the formula Ic where R2, R3 and R4 = alkyl or alkylaryl are to be prepared, the appropriate disorazole of the general formula I is reacted with an appropriate alkylating halide or alkylaryl halide and a suitable base,

preferably triethylamine, pyridine, an alkoxide, sodium hydride or potassium carbonate, in a suitable solvent, for example dichloromethane, diethyl ether, acetonitrile, *NN*-dimethylformamide, between 0 and 100°C (J. Org. Chem. 1971, 36, 284-294).

For instance, if substituted disorazoles as per the formula Ib where R2, R3 and R4 = carbamate, thiocarbamate are to be prepared, the appropriate disorazole of the general formula I can be reacted with appropriate isocyanates or isothiocyanates in the presence of a suitable base, preferably triethylamine, pyridine, sodium hydride, an alkoxide, NaOH in water or potassium carbonate and in a suitable solvent, for example dichloromethane, diethyl ether, acetonitrile, NN-dimethylformamide or solvent mixtures, such as dioxane-water or THF-water mixtures at a temperature between 0 and 100°C (DE2040175, Rocz. Chem. 1972, 46, 717; Tetrahedron Lett. 1993, 34, 3745).

Or, if substituted disorazoles as per the formula Ia where R2, R3 and R4 = alkylcarbonyl or alkoxycarbonyl are to be prepared, the appropriate disorazole of the general formula I can be reacted with appropriate alkylcarbonyl chlorides, alkylcarboxylic anhydrides or chloroformates in the presence of a suitable base, preferably triethylamine, pyridine, sodium hydride, an alkoxide, NaOH in water or potassium carbonate and a suitable solvent, for example dichloromethane, diethyl ether, acetonitrile, NN- dimethyl-formamide or solvent mixtures, such as dioxane-water or THF-water mixtures at a temperature of between 0 and 100°C (J.Org. Chem. 1957, 22, 1551; Synth. Commun. 1997,27,2777; J.Org. Chem. 1959, 24, 774).

The invention will be illustrated in greater detail with the aid of the following examples, without being restricted thereto.

Examples

Use possibilities

Example 1

Disorazoles such as, for example, disorazole E1 are preferred as an active compound in a ready-to-use medicament for the treatment of malignant oncoses such as breast cancer, lung cancer, ovarian cancer, skin cancer, prostate cancer, colonic cancer, renal cell cancer, hepatic cancer, pancreatic cancer and cancers of the brain.

In a preferred administration form, the active compound is present as a lyophilizate

together with the excipients known to the person skilled in the art in an injection bottle and is dissolved using physiological saline solution before use, then diluted in an injection bag and administered to the patient with the aid of a cannula into the vein. The dose, depending on the stage of the oncosis and the state of health of the patient, is between 0.1 mg and 100 mg of active compound per m^2. The infusion period depends on the objective criteria of the disease.

Example 2

Use of disorazoles such as, for example, disorazole E1 as an active compound in a ready-to-use medicament for the treatment of inflammatory diseases. These include, for example, inflammatory airway diseases such as bronchial asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, eczema, allergic angiitis, inflammations mediated by eosinophils such as eosinophilic pneumonia and PIE syndrome (pulmonary infiltration with eosinophilia), urticaria, ulcerative colitis, Crohn's disease and proliferative skin diseases such as psoriasis and keratosis.

Example 3

Use of disorazoles such as, for example, disorazole E1 as an active compound in a ready-to-use medicament having immunomodulatory action for the treatment of immune and autoimmune diseases. Such diseases can include, for example, joint inflammations such as arthritis and rheumatoid arthritis and other arthritic diseases such as rheumatoid spondylitis and osteoarthritis. Further possibilities of use are the treatment of patients who are suffering from sepsis, septic shock, Gram-negative sepsis, toxic shock syndrome,

respiratory distress syndrome, asthma and other chronic pulmonary diseases, bone resorption diseases or transplant rejection reactions or other autoimmune diseases, such as lupus erythematosus, multiple sclerosis, glomerulonephritis and uveitis, insulin-dependent diabetes mellitus and chronic demyelinization.

Example 4

Use of disorazoles such as, example disorazole E1 as an active compound in a ready-to-use medicament which can be employed for the therapy of infections such as virus infections and parasite infections, for example for the therapy of malaria, infection-related fever, infection-related muscle pain, HIV infections (AIDS) and cachexias.

Production

For the administration of the compounds according to the invention, parenteral, transdermal, topical, inhalative and intranasal preparations are preferably suitable.
The production, filling and sealing of the preparations is carried out under the customary antimicrobial and aseptic conditions.

In addition to at least one constituent according to the invention, the pharmaceutical forms, depending on the pharmaceutical form employed, optionally contain excipients, such as, inter alia, solvents, solution accelerators, solubilizers, emulsifiers, wetting agents, antifoams, gel-forming agents, thickeners, buffers, salt-forming agents, preservatives, antioxidants, colorants, taste and odor corrigents. The choice of the excipients and the amounts thereof to be employed depends on the pharmaceutical form chosen and is adapted to the formulations known to the person skilled in the art.

The medicaments according to the invention can be administered in a suitable administration form to the skin, epicutaneously as a solution, suspension, emulsion, foam, ointment, paste or patch; via the nasal mucosa, nasally as drops, ointment, or spray; via the bronchial and alveolar epithelium, pulmonarily or by inhalation as an aerosol or inhalant; via the conjunctiva, conjunctivally as eye drops, eye ointment, eye tablets, lamellae or eye lotion; into an artery, intraarterially as an injection; into a vein, intravenously as an injection or infusion, paravenously as an injection or infusion; into the skin, intracutaneously as an injection or implant; under the skin, subcutaneously as an injection or implant; into the muscle, intramuscularly as an injection or implant; into the abdominal cavity, intraperitoneally as an injection or infusion.

In tumor therapy, the compounds of the general formula I according to the invention can be employed as an individual substance or in combination with further cytotoxic substances, such as, for example, paclitaxel, docetaxel, vincristine, vindesine, cisplatin, carboplatin, doxorubicin, ifosfamide, cyclophosphamide, 5-FU, methotrexate or in combination with immunomodulators or antibodies and in particular in combination with inhibitors of signal transduction, such as, for example, Herceptin, Glivec or Iressa.

Example 5

Preparations for the parenteral administration of disorazoles such as, for example,

disorazole E1, can be present in separate dose unit forms such as, for example, ampoules or vials. Preferably, solutions of the active compound are used, preferably aqueous solutions and especially isotonic solutions or alternatively suspensions. These injection forms can be made available as a ready-to-use preparation or are prepared only directly before use by mixing the active compound, for example the lyophilizate, if appropriate with further solid carriers, with the desired solvent or suspending agent.

Example 6

Preparations for the intranasal administration of disorazoles such as, for example, disorazole E1, can be present as aqueous or oily solutions or as aqueous or oily suspensions. They can also be present as lyophilizates, which are prepared before use using the suitable solvent or suspending agent.

Biological actions of the compounds according to the invention

Example 7 Antiproliferative action on various tumor cell lines

The compounds according to the invention were investigated for their antiproliferative activity in a proliferation test on established tumor cell lines (D.A. Scuderio et al. Cancer Res. 1988, 48, 4827-4833). The test used determines the cellular dehydrogenase activity and makes possible a determination of the cell vitality and indirectly of the cell count. The cell lines used by way of example are the human cervical carcinoma cell line KB/HeLa (ATCC CCL17), the ovarian adenocarcinoma cell line SKOV-3 (ATCC HTB77), the human glioblastoma cell line SF-268 (NCI 503138), the lung carcinoma cell line NCI-H460 (NCI 503473) and the human colon adenocarcinoma cell line RKOP27.

The cytotoxic or growth-inhibiting activity of the compounds described as well as of reference compounds is shown in table 1. The results show a very potent inhibition of the proliferation of selected tumor cell lines by the substances according to the invention.

Example	XTT proliferation assay, EC50 in [µg/ml]				
	KB/Hela	SKOV3	SF-268	NCI-H460	RKOP27
Disorazole E1	0.00005	0.000016	0.00012	0.00003	0.00006
Disorazole D1	0.00015	0.0001	0.00022	0.00015	0.0003
Disrazole A1	0.00015	0.0002	0.00027	0.00015	0.00025
Paclitaxel	0.01	0.01	0.01	0.01	
Vindesine	0.002	0.002	0.005	0.006	

Table 1: Inhibition of proliferation by substances according to the invention in the XTT cytotoxicity test on human tumor cell lines

Example 8 Antiproliferative action on MDR tumor cell lines

For further characterization, the substances according to the invention were investigated against multi-drug-resistant cell lines (MDR) in comparison to the nonresistant wild-type cell lines.

The cell lines investigated are the acute myeloid leukemia cell line LT12 and the resistant line LT12/mdr. Moreover, the murine P388 cell line (methylcholanthrene-induced lymphoid neoplasm) and the doxorubicin-resistant P388 were used as test systems.

The results are shown in summarized form in table 2 below:

	XTT proliferation assay, EC_{50} in [µg/ml]			
Substance	LT12	LT12MDR	P388	P388ADR
Disorazole E1	0.0001	0.004	0.0004	0.001
Paclitaxel	0.005	0.340	0.035	>3.16
Vindesine	0.0009	0.222	0.009	0.94

Table 2: Inhibitory action of disorazole E1 and reference substances in the XTT proliferation test on nonresistant and resistant tumor cell lines.

Disorazole E1 shows a very potent inhibitory action on all cell lines tested, while in the case of the classical tubulin inhibitors such as paclitaxel or vincristine a greatly decreased action and cross resistances to the MDR1 cell lines can be detected.

Example 9 Inhibition of the polymerization of tubulin

The substances were tested in an in-vitro test for inhibition of the polymerization of bovine ß-tubulin (D.M. Bollag et al. Cancer Res. 1995, 55, 2325-2333). In this test, tubulin purified by cycles of polymerization and depolymerization is employed, and is polymerized by addition of GTP and warming. The EC_{50} values of the inhibition of polymerization of ß-tubulin with 30% associated proteins (MAPs) are indicated in table 3.

Substances	EC_{50} in [µg/ml] with 30% MAPs
Disorazole E1	1.50
Disorazole D1	2.50
Disorazole A1	4.8
Vindesine	0.40

experiments: n=2

Table 3: Inhibition of the polymerization of ß-tubulin with 30% MAPs

The results show that the disorazoles E1 and D1 inhibit tubulin polymerization at low concentrations.

Example 10 Cell cycle analysis

The cell cycle comprises the development of the cell from one cell generation to the next.
During the resting phase (G0) and presynthetic phase (G1), the cell has a diploid chromosome set (2c). In the synthesis phase (S), the amount of DNA is increased by replication. The S phase ends by reaching the premitotic phase (G2M), in which the cell has a reduplicated chromosome complement (4c) and doubled DNA content. In the subsequent, transient mitosis phase (M) the uniform division of the reduplicated chromosomes to two daughter cells occurs, which then in each case again show a diploid DNA content and are in the G01 phase, so that the cell cycle can begin anew.

For the cell cycle analysis, KB/HeLa cells were treated with the test substances in different concentrations (0.1-1000 nM) for 24 hours at 37°C.

The percentage proportion of the cells arrested in the G2/M phase of the cell cycle after treatment with reference substances or selected test substances is shown in table 4 below. The results were evaluated using special analysis software (ModFit™).

Example	EC_{50} in [nM] (50% cells in G2/M)
Disorazole E1	1.6
Paclitaxel	46
Vindesine	3.0

Table 4: concentration at which 50% of the cells are arrested in the G2/M phase.

The compounds according to the invention have the highest activities in comparison with the reference compounds. In particular, disorazole E1 inhibits the cell cycle in the G2/M phase in extremely low concentrations.


Example 11 ***In vivo*** **results**

The *in-vivo* activity of the compounds according to the invention was tested on human and murine xenograft models.

In the therapy experiment, with NCI-H460 tumor xenograft-bearing nude mice, it was possible for disorazole E1 administered i.v. to produce a significant reduction of the tumor growth even at doses which produced no significant weight decrease or perhaps even mortality.

Figure 1: *In-vivo* treatment experiment with disorazole E1 in the NCI-H460 tumor xenograft

Model on nude mice



Disorazole E1 (D-42805): 0.25mg/kg; i.v.: day 0, 7; 8 dead (day 11,12,13)

Disorazole E1 (D-42805): 0.1mg/kg; i.v.: day 0,7,14; no cases of death

Disorazole E1 (D-42805): 0.05mg/kg; i.v.: day 0,7,14; no cases of death

Control: 0.9% strength saline solution containing 3.3% DMSO, 10 ml/kg;

n = 8 animals/group

Example 12 AMES test

For the estimation of possible side effects, disorazole E1 was investigated for mutagenicity in a fluctuation assay against the mutant strains TA98 and TA100 of the bacterium *Salmonella typhimurium* at three concentrations (2.5; 5 and 10µM). The mutagenicity investigations were further carried out in the presence of the rat liver enzyme S9.

The results are compiled in table 5 below:

Compound	Conc. [µM]	AMES TA98 without S9	AMES TA98 with S9	AMES TA100 without S9	AMES TA100 with S9
Disorazole E1	10	**inactive**	**inactive**	**inactive**	**inactive**
Disorazole E1	5	**inactive**	**inactive**	**inactive**	**inactive**
Disorazole E1	2.5	**inactive**	**inactive**	**inactive**	**inactive**

Table 5: Investigation of **disorazole E1** for mutagenicity

Disorazole E1 shows no effects under the assay conditions described in the abovementioned concentrations, it is thus AMES test-inactive.

Example 13 Influence on protein biosynthesis and nonproliferating cells

For the estimation of the possible side-effect potential, the influence of disorazole E1 on nonproliferating cells and on the protein biosynthesis was investigated (table 6).

Substance	Conc. [µM]	Surviving cells, primary human hepatocytes[1] Average, % of control	Protein synthesis[2] Average, % of control
Disorazole E1	**1**	**119.6**	**95.9**

1) Tested with alamarBlue, human primary hepatocytes, n = 3;


2) Tested via the incorporation of ^{14}C-methionine, human hepatocellular carcinoma cells (HepG2), n= 2;

Table 6: Influence of disorazole E1 on nonproliferating cells and on the protein biosynthesis

The results of table 6 show that disorazole E1 neither acts negatively on the protein biosynthesis nor on the survival of nonproliferating cells.

Patent claims

1. A medicament containing at least one disorazole derivative of the general formula I



Formula I

in which independently of one another

R1 is:

(i) hydrogen
(ii) OR4
(iii) part of a double bond to C5'

R2, R3 and R4 are:

(i) hydrogen
(ii) unsubstituted or substituted (C_1-C_6)-alkyl,
(iii) (C_1-C_4)-alkyl substituted by one or more fluorine atoms, preferably a trifluoromethyl group,
(iv) unsubstituted or substituted (C_1-C_4)-alkyl-(C_6-C_{14})-aryl, unsubstituted or substituted (C_1-C_4)-alkylheteroaryl,

(v) (C_1-C_4)-alkoxycarbonyl, (C_1-C_4)-alkylaminocarbonyl (C_1-C_4)-alkylamino-thiocarbonyl, (C_1-C_6)-alkylcarbonyl or (C_1-C_6)-alkoxycarbonyl-(C_1-C_6)-alkyl,

it being possible for the substitution of the alkyl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, NH-(C_3-C_{12})-cycloalkyl, OH, O-(C_1-C_{20})-alkyl to take

place singly or, on identical or different atoms, multiply by identical or different substituents, and it being possible for the substitution of an aryl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, OH, O-(C_1-C_{20})-alkyl and/or (C_3-C_8)-heterocyclyl having 1 to 5 heteroatoms, preferably nitrogen, oxygen, sulfur to take place singly or, on identical or different atoms, multiply by identical or different substituents,

and


X, Y are: in each case individually independently of one another or together oxygen, sulfur, two vicinal hydroxyl groups, two vicinal methoxy groups, part of a double bond,

a compound being excluded in which R1 is methoxy, R2, R3 are hydrogen, X is oxygen and Y is the part of a double bond,

its tautomers, E/Z isomers, stereoisomers, including the diastereomers and enantiomers, and the physiologically tolerable salts thereof.

2. The medicament as claimed in claim 1, containing the disorazole derivative and pharmaceutically utilizable carriers and/or diluents and excipients in the form of solutions, suspensions, emulsions, foams, ointments, pastes, patches or implants for administration.

3. The use of disorazole derivatives of the general formula I



Formula 1

in which independently of one another

R1 is:

(i) hydrogen

(ii) OR4

(iii) part of a double bond to C5'

R2, R3 and R4 are:

(i) hydrogen

(ii) unsubstituted or substituted (C_1-C_6)-alkyl,

(iii) (C_1-C_4)-alkyl substituted by one or more fluorine atoms, preferably a trifluoromethyl group,

(iv) unsubstituted or substituted (C_1-C_4)-alkyl-(C_6-C_{14})-aryl, unsubstituted or substituted (C_1-C_4)-alkylheteroaryl,

(v) (C_1-C_4)-alkoxycarbonyl, (C_1-C_4)-alkylaminocarbonyl (C_1-C_4)-alkylamino-thiocarbonyl, (C_1-C_6)-alkylcarbonyl or (C_1-C_6)-alkoxycarbonyl-(C_1-C_6)-alkyl,

it being possible for the substitution of the alkyl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, NH-(C_3-C_{12})-cycloalkyl, OH, O-(C_1-C_{20})-alkyl to take place singly or, on identical or different atoms, multiply by identical or different substituents, and it being possible for the substitution of an aryl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, OH, O-(C_1-C_{20})-alkyl and/or (C_3-C_8)-heterocyclyl having 1 to 5 heteroatoms, preferably nitrogen, oxygen, sulfur to take place singly or, on identical or different atoms, multiply by identical or different substituents,

and

X, Y are: in each case individually independently of one another or together oxygen, sulfur, two vicinal hydroxyl groups, two vicinal methoxy groups, part of a double bond,

a compound being excluded in which R1 is methoxy, R2, R3 are hydrogen, X is oxygen and Y is the part of a double bond,

its tautomers, E/Z isomers, stereoisomers, including the diastereomers and enantiomers, and the physiologically tolerable salts thereof, for the production of a medicament for the treatment of benign or malignant oncoses in humans or animals.

4. The use of disorazole derivatives of the general formula I as claimed in claim 3 for the treatment of oncoses alone or in combination with cytotoxic substances and/or inhibitors of signal transduction.

5. The use of disorazole derivatives of the general formula I for the production of a medicament for the treatment of a disease in humans or animals which is based on the rapid and uncontrolled proliferation of endogenous cells.

6. The use of disorazole derivatives of the general formula I for the production of a medicament for the treatment of diseases which respond to immunomodulatory action, such as psoriasis, arteriosclerosis, arthritis, keratosis, muliple sclerosis and cancer.

7. The use of disorazole derivatives of the general formula I for the production of a medicament for the treatment of infective diseases, such as cachexia, malaria, AIDS and infection-related fever and pain.

8. The use of disorazole derivatives of the general formula I for the production of a medicament for the treatment of inflammatory and allergic diseases, inflammations mediated by eosinophils or proliferative diseases such as airway diseases, bronchial asthma, allergic rhinitis, allergic conjunctivitis, eczema and Crohn's disease.

9. The use of the disorazole derivative E1 of the general formula I, in which R1 and R2 are hydrogen, R3 is methyl and X and Y are oxygen, as claimed in claim 3, for the production of a medicament for the treatment of benign or malignant oncoses in humans or animals.

10. The use of a disorazole derivative of the general formula I as claimed in claim 9 for the production of a medicament for the treatment of breast cancer, ovarian cancer, lung cancer, skin cancer, prostate cancer, renal cancer, hepatic cancer, pancreatic

cancer, colonic cancer and cancers of the brain in humans.

11. The use of a disorazole derivative of the general formula I as claimed in claims 9 and 10 for the production of a medicament for the treatment of benign or malignant oncoses in humans or animals in combination with other antitumor agents.

12. The use of a disorazole derivative of the general formula I as claimed in claims 9 to 11 for the production of a medicament for the treatment of benign or malignant oncoses in humans or animals in combination with paclitaxel, docetaxel, vincristine, vindesine, cisplatin, carboplatin, doxorubicin, ifosfamide, cyclophosphamide, 5-FU, methotrexate or in combination with immunomodulators or antibodies and in particular in combination with inhibitors of signal transduction such as Herceptin, Glivec or Iressa and others.